Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Effect of methotrexate on relapse after bone-marrow transplantation for acute lymphoblastic leukaemia. International Bone Marrow Transplant Registry. Lancet 1989 Mar 11;1(8637):535-7 PMID: 2564066

Pubmed ID



Data from 634 patients who received HLA-identical bone-marrow transplants for acute lymphoblastic leukaemia in first or second remission were analysed to examine the influence of mode of prophylaxis against graft versus host disease on rate of relapse of leukaemia. Methotrexate was associated with a significantly lower risk of leukaemia recurrence than were other methods of GVHD prophylaxis (relative risk 0.2, p less than 0.0003, for first-remission transplants; relative risk 0.3, p less than 0.0001, for second remission transplants). The decreased risk of relapse did not seem to be mediated via an impact on incidence or severity of graft versus host disease. A direct antileukaemia effect of methotrexate is the most likely mechanism.


Mary M. Horowitz MD, MS Center Director, Professor in the Medicine department at Medical College of Wisconsin


2-s2.0-0024508232   19 Citations

MESH terms used to index this publication - Major topics in bold

Actuarial Analysis
Bone Marrow Transplantation
Drug Evaluation
Graft vs Host Disease
Multicenter Studies as Topic
Neoplasm Recurrence, Local
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Retrospective Studies
jenkins-FCD Prod-331 a335b1a6d1e9c32173c9534e6f6ff51494143916